May 16, 2018 Bionure initiates a Phase 1 clinical trial of its lead compound BN201 in the United Kingdom
BN201 is a first-in-class selective SGK2 agonist that promotes remyelination and neuroprotection, offering a game-changing solution for neurodegenerative diseases.
The company has reconstituted its Board of Directors and added prominent neuro-ophthalmologist Dr. Craig Smith as the new CMO
Bionure, Barcelona based biotech company that develops neuroprotectant agents to treat neurodegenerative diseases primarily focusing on rare ophthalmologic diseases as Acute Optic Neuritis (AON) and Neuromyelitis Optica (NMO), announces today the initiation of a Phase 1 clinical trial of its lead compound BN201 in the United Kingdom.
BN201 is a first-in-class compound that promotes cell survival and endogenous natural repair by activating SKG2, an intracellular serine/threonine kinase that plays a crucial role in the response of neurons to stress and its survival. The Phase 1 clinical trial is intended to investigate safety, tolerability and pharmacokinetics of single and multiple doses of BN201 in healthy volunteers. Results are expected by the end of the year and the company’s plan is to start a Phase 2a trial in 2019.